Data gathered: January 13
AI Stock Analysis - Marinus Pharmaceuticals (MRNS)
Analysis generated December 26, 2024. Powered by Chat GPT.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative therapeutic solutions for rare seizure disorders. Marinus’s flagship product, ganaxolone, is a neuroactive steroid that has demonstrated efficacy in seizure control. With a pipeline focused on various formulations and indications, Marinus is a critical player in the niche market of neurological pharmaceuticals.
Stock Alerts - Marinus Pharmaceuticals (MRNS)
 |
Marinus Pharmaceuticals | December 30 Price is up by 42.4% in the last 24h. |
|
Marinus Pharmaceuticals | December 27 Price is down by -5.5% in the last 24h. |
|
Marinus Pharmaceuticals | December 26 Price is up by 7.7% in the last 24h. |
|
Marinus Pharmaceuticals | December 24 Price is up by 5% in the last 24h. |
Alternative Data for Marinus Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,337 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapies to treat rare seizure disorders. The company is headquartered in Radnor, Pennsylvania.
| Price | $0.54 |
| Target Price | Sign up |
| Volume | 2,370,000 |
| Market Cap | $30M |
| Year Range | $0.23 - $1.9 |
| Dividend Yield | 0% |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
 |
Analysts Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target at $4.79January 10 - ETF Daily News |
 |
Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should KnowJanuary 10 - Yahoo |
Kuehn Law Encourages MRNS, OMIC, LBRDA, and VCSA Investors to Contact Law FirmJanuary 6 - GlobeNewswire |
|
 |
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.comJanuary 5 - ETF Daily News |
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MoneyLion Inc. (NYSE - ML), Marinus Pharmaceuticals, Inc. (Nasdaq - MRNS), Better Choice Inc. (NYSE American - BTTR), NeueHealth, Inc. (NYSE - NEUE)January 3 - GlobeNewswire |
|
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – VINC, VCSA, MRNS, MHLDJanuary 2 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 8.5M | 13M | -4M | -24M | 0 | 0.000 |
| Q2 '24 | 8.1M | 19M | -11M | -36M | -30M | -0.600 |
| Q1 '24 | 7.7M | 19M | -11M | -39M | -36M | -0.680 |
| Q4 '23 | 7.2M | 16M | -8.7M | -42M | -35M | -0.740 |
| Q3 '23 | 7.3M | 15M | -7.5M | -33M | -32M | -0.610 |
Insider Transactions View All
| Hulihan Joseph filed to sell 72,725 shares at $1.1. August 7 '24 |
| MANNING MARTHA E filed to sell 60,263 shares at $1.1. August 7 '24 |
| Pfanstiel Steven filed to sell 79,773 shares at $1.1. August 7 '24 |
| Shafer Christina filed to sell 67,406 shares at $1.1. August 7 '24 |
| Braunstein Scott filed to sell 298,667 shares at $1.1. August 7 '24 |
Similar companies
Read more about Marinus Pharmaceuticals (MRNS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Marinus Pharmaceuticals?
The Market Cap of Marinus Pharmaceuticals is $30M.
What is the current stock price of Marinus Pharmaceuticals?
Currently, the price of one share of Marinus Pharmaceuticals stock is $0.54.
How can I analyze the MRNS stock price chart for investment decisions?
The MRNS stock price chart above provides a comprehensive visual representation of Marinus Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Marinus Pharmaceuticals shares. Our platform offers an up-to-date MRNS stock price chart, along with technical data analysis and alternative data insights.
Does MRNS offer dividends to its shareholders?
As of our latest update, Marinus Pharmaceuticals (MRNS) does not offer dividends to its shareholders. Investors interested in Marinus Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Marinus Pharmaceuticals?
Some of the similar stocks of Marinus Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.